FMP
Medtronic plc
MDT
NYSE
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
89.25 USD
1.41 (1.58%)
Mr. Geoffrey Straub Martha
Healthcare
Medical - Devices
NYSE
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The compan...
0001613103
IE00BTN1Y115
G5960L103
20 On Hatch
353 1 438 1700
IE
95,000
May 2, 1973
0001613103
NYSE
Medical - Devices
Healthcare
G5960L103
IE00BTN1Y115
IE
89.25
0.85
6.63M
114.44B
-
75.96-92.68
95.98
-
-
-
-
27.29
-
https://www.medtronic.com
Rating Distribution
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Andrew Wynn
Nov 20, 2024
Medtronic (NYSE:MDT) is a leading global healthcare technology company that specializes in medical devices and therapies. It operates in various segments, including cardiovascular, diabetes, and surgical technologies. Medtronic competes with other major players in the medical device industry, such as Johnson & Johnson and Boston Scientific. The company is known for its innovative products and solutions that improve patient outcomes. On November 19, 2024, Medtronic reported earnings per share (E...
The Motley Fool
Aug 26, 2024
Medtronic delivered a strong first-quarter earnings report. The company benefits from continued market adoption of several new product launches over the past year.
Seeking Alpha
Aug 25, 2024
Medtronic faced challenges, including poor focus, lack of innovation, and COVID-19 impact, leading to share price stagnation since 2018. Despite recent improvements in performance, Medtronic remains undervalued with solid competitive advantages and a promising dividend streak. The company's focus on innovation, strong market position, and dividend growth potential make it a long-term buy for conservative investors.
MarketBeat
Aug 23, 2024
Shares of medical device manufacturer Medtronic PLC NYSE: MDT are down about 35% from their highs of roughly three years ago, but promising results from the company's first quarter of fiscal 2025, which ended July 26, could help to drive renewed upward momentum. Specifically, Medtronic's diabetes and neuromodulation products may be poised for breakout growth, and the company's up-and-coming products in various stages of development offer promise as well.
Forbes
Aug 22, 2024
Medtronic (NYSE: MDT) recently reported its Q1 fiscal 2025 results (fiscal ends in April), with revenues and earnings exceeding our estimates. The company reported revenue of $7.9 billion and adjusted earnings of $1.23 per share, compared to our estimates of $7.9 billion and $1.21, respectively.
Zacks Investment Research
Aug 21, 2024
Although the revenue and EPS for Medtronic (MDT) give a sense of how its business performed in the quarter ended July 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
CNBC Television
Aug 20, 2024
Geoff Martha, Medtronic CEO, joins 'Money Movers' to discuss the company's quarterly earnings results, where the company's business is toughest, and much more.
Zacks Investment Research
Aug 20, 2024
Medtronic (MDT) reports broad-based growth across all major segments, with strong gains in Cardiac Rhythm & Heart Failure, Structural Heart & Aortic, Cranial & Spinal Technologies and Diabetes businesses.